Wellcome funding boost for Bharat and Maryland's Salmonella vaccine
This article was originally published in Scrip
The University of Maryland School of Medicine's Center for Vaccine Development (CVD) and Bharat Biotech of India have been granted a $4 million strategic translation award from The Wellcome Trust to develop CVD's conjugate vaccine to prevent the potentially lethal infectious disease caused by invasive non-typhoidal Salmonella (NTS).
You may also be interested in...
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.